We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02184767
Recruitment Status : Completed
First Posted : July 9, 2014
Last Update Posted : November 12, 2021
Information provided by (Responsible Party):
Teva Branded Pharmaceutical Products R&D, Inc.

Brief Summary:
This study is to assess the pharmacokinetics of loxapine and will be using plasma concentration data obtained over 48 hours after administration of the study drug

Condition or disease Intervention/treatment Phase
BiPolar Drug: ADASUVE® Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Nonrandomized, Open-Label, Multicenter, Phase 1 Study to Assess the Safety and Pharmacokinetics of ADASUVE® (STACCATO® Loxapine for Inhalation) at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication
Study Start Date : July 2014
Actual Primary Completion Date : March 2015
Actual Study Completion Date : May 2015

Arm Intervention/treatment
Experimental: ADASUVE®
oral inhalation using a single-use, hand-held, inhaler; dosage determined by the investigator according the participants weight
ADASUVE® 2.5, 5, or 10 mg
Other Name: STACCATO® Loxapine for Inhalation

Primary Outcome Measures :
  1. area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t) [ Time Frame: 48 hours ]

Secondary Outcome Measures :
  1. area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) [ Time Frame: 48 hours ]
  2. ratio of AUC0-t to AUC0-inf (AUC0-t/AUC0-inf) [ Time Frame: 48 hours ]
  3. maximum observed plasma drug concentration (Cmax) [ Time Frame: 48 hours ]
  4. time to maximum observed concentration (tmax) [ Time Frame: 48 hours ]
  5. apparent terminal elimination rate constant (Kel) [ Time Frame: 48 hours ]
  6. elimination half-life (t½) [ Time Frame: 48 hours ]
  7. apparent clearance (CL/F) [ Time Frame: 48 hours ]
  8. volume of distribution (V/F) [ Time Frame: 48 hours ]
  9. The palatability of ADASUVE will be performed using a visual analog scale (VAS) [ Time Frame: 2 1/2 weeks ]
  10. Summary of participants with adverse events [ Time Frame: 3 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   10 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  1. Written informed consent is obtained from each patient's parent or legal guardian and written assent is obtained from each patient.
  2. The patient is a boy or girl 10 through 17 years of age.
  3. The patient is within the 2.5 to 97.5 percentile for body mass index (BMI) on the basis of age and sex and is within the following weight range, as appropriate:

    • boys: more than 27 kg and 127 kg or less
    • girls: more than 27 kg and 111 kg or less
  4. The patient has a documented history of schizophrenia, bipolar disorder, autism, or any condition for which the use of antipsychotic medication (eg, risperidone, olanzapine, aripirazole, haloperidol, etc.) is warranted and/or administered. Note: Patients currently receiving treatment for any condition must be on a stable regimen (dose and frequency) for a minimum of 28 days before administration of ADASUVE.
  5. The patient is in good general health as determined by a complete medical history (including psychiatric and respiratory), clinical laboratory tests (include hematology, serum chemistry, and urinalysis), physical examination, body weight, 12-lead ECG, spirometry, vital signs measurements (blood pressure [systolic and diastolic], heart rate, body temperature, and respiratory rate), pulse oximetry, chest auscultation, neurologic examination, suicidality assessment, and concomitant medication usage inquiry.
  6. Female patients who are postmenarche or sexually active must have a negative pregnancy test result, must have exclusively same sex partners or be using an acceptable method of contraception, and must agree to continued use of this method for the duration of the study and for 30 days after discontinuation of ADASUVE. Acceptable methods of contraception include abstinence or an intrauterine device (known to have a failure rate of less than 1% per year).
  7. The patient has negative alcohol test and urine drug screen (UDS) results. A positive UDS result with appropriate medical explanation (eg, prescribed amphetamines) may be permitted after consultation with the medical monitor. Note: The UDS will also detect the presence of tetrahydrocannabinol (THC). A positive result for THC may be permitted after discussion with the sponsor if the result is low and is consistent (eg, positive at all predose assessments). If a patient tests negative for THC at screening, the result must remain negative at check-in for the patient to be eligible for study participation.
  8. The patient and parent/legal guardian must be willing and able to comply with study restrictions and to remain at the investigational center for the required duration at each visit.


  1. The patient has any clinically significant uncontrolled medical condition (treated or untreated) other than the conditions specified in inclusion criterion d.
  2. The patient has a current diagnosis or history of asthma, chronic obstructive pulmonary disease (COPD), bronchiolitis, chronic bronchitis, emphysema, or other lung disease associated with bronchospasm.
  3. The patient has acute respiratory signs or symptoms (eg, wheezing)
  4. The patient currently has or has a known history of the following:

    • cardiovascular disease (including, but not limited to, myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities)
    • cerebrovascular disease
    • conditions that predispose him or her to hypotension (including, but not limited to, dehydration, hypovolemia, or treatment with antihypertensive medications or other drugs that affect blood pressure or reduce heart rate)
    • seizure disorder except a history of infantile febrile seizures
  5. The patient is pregnant or lactating.
  6. The patient is febrile.
  7. The patient has any other disease or condition that, in the investigator's or medical monitor's opinion, would present undue risk to the patient, or may confound the interpretation of study results.
  8. The patient has taken any of the following drugs, substances, or foods:

    • any investigational drug within 30 days or 5 half-lives (whichever is longer) before administration of ADASUVE or, in the case of a new chemical entity, 3 months or 5 half-lives (whichever is longer) before administration of ADASUVE
    • current use of medications to treat airway disease such as asthma or COPD
    • loxapine or amoxapine within the last 30 days
    • more than 21 units of alcohol per week within the past 2 years or a history of alcohol, narcotic, or any other substance abuse or dependence as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR, American Psychiatric Association 2000). Note: A unit of alcohol is equal to 1 ounce of hard liquor, 5 ounces of wine, or 8 ounces of beer.
    • clinically significant excessive consumption of coffee, tea, and/or other caffeine-containing beverage or food (ie, 600 mg of caffeine or more per day, or 12-ounce caffeine-containing sodas, 30 ounces of chocolate, or 5 or more cups of coffee per day), or a combination of any of these beverages or foods within 2 weeks before the dose of ADASUVE
    • nicotine-containing products (including but not limited to cigarettes, cigars, and chewing or dipping tobacco) within 12 months before administration of ADASUVE or use of topical or oral nicotine preparations for smoking cessation within the past 3 months before administration of ADASUVE
  9. The patient has a known sensitivity or idiosyncratic reaction to loxapine or amoxapine, any compound present in the study formulation, any metabolites, or any other related compounds.
  10. The patient has a history of any clinically significant cutaneous drug reaction, or a history of clinically significant hypersensitivity reaction, including multiple allergies or drug reactions.
  11. The patient has a known history of contraindications to anticholinergics (eg, bowel obstructions, urinary retention, or acute glaucoma).
  12. The patient has any procedure or disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery; a history of appendectomy is allowed).
  13. The patient has received or donated blood or blood products (eg, plasma or platelets) in the 3 months before administration of ADASUVE or has made more than 2 blood (≥ 450 mL) or blood product donations within the 12 months before administration of ADASUVE, or has plans to donate during the study or within 3 months after completion of the study.
  14. The patient has 1 or more clinical laboratory test values outside the range specified below, or any other clinically significant laboratory abnormality, as determined by the investigator or medical monitor:

    • hemoglobin value of less than 11.0 g/dL
    • more than twice the upper limit of the normal range (ULN)
    • total bilirubin value of more than the ULN
  15. With the exception of the conditions specified in inclusion criterion d, the patient has had, within 4 weeks before administration of ADASUVE, a clinically significant illness or, within 1 week before administration of ADASUVE, has had any acute illness, or at screening or on the day before administration of ADASUVE, has symptoms of any clinically significant or acute illness.
  16. The patient has a positive test result for hepatitis B surface antigen (HBsAg) or antibodies to hepatitis C virus, or has a known positive human immunodeficiency virus (HIV) history.
  17. The patient is unable to tolerate direct venipuncture.
  18. The patient has blood pressure outside the range of 90 to 140 mm Hg (systolic) or 50 to 90 mm Hg (diastolic). Note: Only 2 rechecks are permissible for study eligibility purposes.
  19. The patient has, after resting for 5 minutes, an oxygen saturation at less than 95%. Note: Only 2 rechecks are permissible for study eligibility purposes.
  20. The patient has evidence of a clinically significant ECG abnormality.
  21. The patient has a forced expiratory volume in 1 second (FEV1) of less than 80% of predicted value on spirometry.
  22. The patient is unlikely to comply with the study protocol, or is unsuitable for any other reasons, as judged by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02184767

Layout table for location information
United States, Georgia
Teva Investigational Site 12468
Atlanta, Georgia, United States
United States, Ohio
Teva Investigational Site 12469
Cincinnati, Ohio, United States
Sponsors and Collaborators
Teva Branded Pharmaceutical Products R&D, Inc.
Layout table for investigator information
Study Director: Sponsor Medical Expert, MD Teva Branded Pharmaceutical Products R&D, Inc.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Teva Branded Pharmaceutical Products R&D, Inc.
ClinicalTrials.gov Identifier: NCT02184767    
Other Study ID Numbers: TV571-CNS-10018
First Posted: July 9, 2014    Key Record Dates
Last Update Posted: November 12, 2021
Last Verified: November 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action